THIOPYRANOL[2,3,4-C,D] INDOLES AS INHIBITORS OF 5-LIPOXYGENASE, 5-LIPOXYGENASE-ACTIVATING PROTEIN, AND LEUKOTRIENE C-4 SYNTHASE

被引:36
作者
HUTCHINSON, JH
CHARLESON, S
EVANS, JF
FALGUEYRET, JP
HOOGSTEEN, K
JONES, TR
KARGMAN, S
MACDONALD, D
MCFARLANE, CS
NICHOLSON, DW
PIECHUTA, H
RIENDEAU, D
SCHEIGETZ, J
THERIEN, M
GIRARD, Y
机构
[1] MERCK FROSST CTR THERAPEUT RES,DEPT MED CHEM,DORVAL,PQ H9R 4P8,CANADA
[2] MERCK FROSST CTR THERAPEUT RES,DEPT PHARMACOL,DORVAL,PQ H9R 4P8,CANADA
[3] MERCK FROSST CTR THERAPEUT RES,DEPT BIOCHEM,DORVAL,PQ H9R 4P8,CANADA
关键词
D O I
10.1021/jm00022a020
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The attachment of an arylacetic or benzoic acid moiety to the thiopyrano[2,3,4-c,d]indole nucleus results in compounds which are highly potent and selective 5-lipoxygenase (5-LO) inhibitors. These compounds are structurally simpler than previous compounds of similar potency in that they contain a single chiral center. From the data presented, 2-[[1-(3-chlorobenzyl)-4-methyl-6-[(5-phenylpyridin-2-yl)methoxy]-4,5-dihydro-1H-thiopyrano [2,3,4-c,d]indol-2-yl]methoxy]phenylacetic acid, 14b, was shown to inhibit 5-hydroperoxyeicosatetraenoic acid (5-HPETE) production by human 5-LO (IC50 of 18 nM). The acid 14b is highly selective as an inhibitor of 5-LO activity when compared to the inhibition of ram seminal vesicle cyclooxygenase (IC50 > 5 mu M) or human leukocyte leukotriene A(4) (LTA(4)) hydrolase (IC50 > 20 mu M). In addition, 14b was inactive in a 5-lipoxygenase-activating protein (FLAP) binding assay at 10 mu M. In vivo studies showed that 14b is bioavailable in rat and functionally active in the hyperreactive rat model of antigen-induced dyspnea (74% inhibition at 0.5 mg/kg po; 2 h pretreatment). In the conscious squirrel monkey model of asthma, 14b showed excellent functional activity at 0.1 mg/kg against antigen-induced bronchoconstriction (94% inhibition of the increase in R(L) and 100% inhibition in the decrease in C-dyn; n = 4) Resolution of this compound gave (-)-14b, the most potent enantiomer (IC50 = 10 nM in the human 5-LO assay), which was shown to possess the S configuration at the chiral center by X-ray crystallographic analysis of an intermediate. Subsequent studies on the aryl thiopyrano[2,3,4-c,d]indole series of inhibitors led to the discovery of potent dual inhibitors of both FLAP and 5-LO, the most potent of which is 2-[[1-(4-chlorobenzyl)-4-methyl-6-(quinolin-2-ylmethoxy) -4,5-dihydro-1H-thiopyrano[2,3,4-c,d]indol-2-yl]methoxy]phenylacetic acid, 19. Acid 19 has an IC50 of 100 nM for the inhibition of 5-HPETE production by human 5-LO and is active in a FLAP binding assay with an IC50 of 32 nM. Furthermore, thiopyrano[2,3,4-c,d]indoles such as 1 and 14b are capable of inhibiting the LTC(4) synthase reaction in a dose dependent manner (IC(50)s of 11 and 16 mu M, respectively, compared to that of LTC(2) at 1.2 mu M) in contrast to other, structurally distinct 5-LO inhibitors. It has also been observed that the thiopyrano[2,3,4-c,d]indole class of compounds strongly promotes the translocation of 5-LO from the cytosol to a membrane fraction in the presence or absence of the ionophore A23187. The membrane-bound 5-LO retains its activity, and this association with the membrane is not reversed with the FLAP inhibitor MK-886. These observations, in part, support the hypothesis that these compounds act by binding at the arachidonic acid-binding site on FLAP, 5-LO, and LTC(4) synthase and that the thiopyrano[2,3,4-c,d]indole is capable of mimicking an active conformation of arachidonic acid.
引用
收藏
页码:4538 / 4547
页数:10
相关论文
共 44 条
[1]   5-LIPOXYGENASE-ACTIVATING PROTEIN STIMULATES THE UTILIZATION OF ARACHIDONIC-ACID BY 5-LIPOXYGENASE [J].
ABRAMOVITZ, M ;
WONG, E ;
COX, ME ;
RICHARDSON, CD ;
LI, C ;
VICKERS, PJ .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1993, 215 (01) :105-111
[2]   THE 3-DIMENSIONAL STRUCTURE OF AN ARACHIDONIC-ACID 15-LIPOXYGENASE [J].
BOYINGTON, JC ;
GAFFNEY, BJ ;
AMZEL, LM .
SCIENCE, 1993, 260 (5113) :1482-1486
[3]   PHARMACOLOGY OF MK-0591 (3-[1-(4-CHLOROBENZYL)-3-(T-BUTYLTHIO)-5-(QUINOLIN-2-YL-METHOXY)-INDOL-2-YL]-2,2-DIMETHYL PROPANOIC ACID), A POTENT, ORALLY ACTIVE LEUKOTRIENE BIOSYNTHESIS INHIBITOR [J].
BRIDEAU, C ;
CHAN, C ;
CHARLESON, S ;
DENIS, D ;
EVANS, JF ;
FORDHUTCHINSON, AW ;
FORTIN, R ;
GILLARD, JW ;
GUAY, J ;
GUEVREMONT, D ;
HUTCHINSON, JH ;
JONES, TR ;
LEGER, S ;
MANCINI, JA ;
MCFARLANE, CS ;
PICKETT, C ;
PIECHUTA, H ;
PRASIT, P ;
RIENDEAU, D ;
ROUZER, CA ;
TAGARI, P ;
VICKERS, PJ ;
YOUNG, RN ;
ABRAHAM, WM .
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 1992, 70 (06) :799-807
[4]  
CHARLESON S, 1992, MOL PHARMACOL, V41, P873
[5]   STRUCTURAL REQUIREMENTS FOR THE BINDING OF FATTY-ACIDS TO 5-LIPOXYGENASE-ACTIVATING PROTEIN [J].
CHARLESON, S ;
EVANS, JF ;
LEGER, S ;
PERRIER, H ;
PRASIT, P ;
WANG, ZY ;
VICKERS, PJ .
EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, 1994, 267 (03) :275-280
[6]  
CHAURET N, 1995, DRUG METAB DISPOS, V23, P65
[7]  
COLLAWN C, 1992, AM J GASTROENTEROL, V323, P342
[8]  
DENIS D, 1991, J BIOL CHEM, V266, P5072
[9]   THE EFFECT OF MK-0591, A NOVEL 5-LIPOXYGENASE ACTIVATING PROTEIN INHIBITOR, ON LEUKOTRIENE BIOSYNTHESIS AND ALLERGEN-INDUCED AIRWAY RESPONSES IN ASTHMATIC SUBJECTS IN-VIVO [J].
DIAMANT, Z ;
TIMMERS, MC ;
VANDERVEEN, H ;
FRIEDMAN, BS ;
DESMET, M ;
DEPRE, M ;
HILLIARD, D ;
BEL, EH ;
STERK, PJ .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1995, 95 (01) :42-51
[10]   REQUIREMENT OF A 5-LIPOXYGENASE-ACTIVATING PROTEIN FOR LEUKOTRIENE SYNTHESIS [J].
DIXON, RAF ;
DIEHL, RE ;
OPAS, E ;
RANDS, E ;
VICKERS, PJ ;
EVANS, JF ;
GILLARD, JW ;
MILLER, DK .
NATURE, 1990, 343 (6255) :282-284